Misplaced Pages

Lavoltidine

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	Development terminated
Identifiers
IUPAC name propylamino]-1,2,4-triazol-3-yl]methanol
CAS Number	76956-02-0
PubChem CID	55473
ChemSpider	50093
UNII	X16K5179V5
CompTox Dashboard (EPA)	DTXSID0020785
Chemical and physical data
Formula	C19H29N5O2
Molar mass	359.474 g·mol
3D model (JSmol)	Interactive image
SMILES OCc1nn(C)c(n1)NCCCOc2cccc(c2)CN3CCCCC3

Lavoltidine (INN, USAN, BAN; previously known as loxtidine; development code AH-23,844) is a highly potent and selective H₂ receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline) as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.

See also

• H₂ receptor antagonist
• Sufotidine (analogous sequence in which a sulfonyl group replaces the hydroxyl group)

References

1. "International Nonproprietary Names for Pharmaceutical Substances. Recommended International Nonproprietary Names (Rec. INN): List 30" (PDF). WHO Drug Information. 4 (3). World Health Organization: 7. 1990. Retrieved 12 January 2016.
2. "Drug Profile: Lavoltidine". AdisInsight. Springer International Publishing AG. Retrieved 12 January 2016.
3. Washington N (1991). Antacids and anti-reflux agents. Boca Raton: CRC Press. ISBN 0-8493-5444-7.
4. Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8.

• Drugs not assigned an ATC code
• Abandoned drugs
• Primary alcohols
• Amines
• H2 receptor antagonists
• 1-Piperidinyl compounds
• Triazoles
• Phenol ethers